What is the Unicycive Therapeutics securities class action lawsuit about?

The lawsuit alleges Unicycive misled investors about manufacturing compliance risks involving a third-party vendor and OLC’s FDA approval prospects, including whether the vendor had resolved FDA-cited deficiencies.

Who may be eligible to participate in the Unicycive Therapeutics investor lawsuit?

Investors who purchased or acquired Unicycive (NASDAQ: UNCY) securities between December 29, 2025 and June 29, 2026 and suffered losses may be eligible to participate in the securities class action.

Why is Unicycive Therapeutics accused of misleading investors about OLC?

The complaint alleges Unicycive had not inspected or audited its manufacturing vendor’s facility for cGMP compliance, yet lacked a reasonable basis to believe FDA-cited deficiencies were resolved or that OLC approval would not be delayed.

What manufacturing problems are alleged in the Unicycive Therapeutics lawsuit?

The complaint alleges Unicycive failed to inspect or audit its third-party manufacturer’s cGMP compliance and did not adequately disclose the risk that the FDA could seek additional manufacturing information, potentially delaying OLC approval.

What is the lead plaintiff deadline for the Unicycive Therapeutics securities lawsuit?

The deadline to seek appointment as lead plaintiff in the Unicycive Therapeutics securities class action is November 2, 2026. The lead plaintiff represents the proposed investor class and helps oversee the litigation.

Unicycive Therapeutics, Inc. - Faruqi & Faruqi LLP

Unicycive Therapeutics, Inc.

Join Action

Case Details

Ticker UNCY

Class Period 12/29/2025 - 06/29/2026

Lead Plaintiff Deadline 11/02/2026

Days Left to Seek Lead Plaintiff

If you are a Unicycive investor who suffered a loss and would like to learn more, you can provide your information below:

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Unicycive between December 29, 2025 and June 29, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY) and reminds investors of the November 2, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose: (1) that the Company had not inspected its third-party manufacturing vendor’s facility or otherwise audited the facility’s compliance with current good manufacturing practices; (2) that, as a result, the Company lacked a reasonable basis to believe that the vendor had resolved the FDA’s cited deficiencies; (3) that there was an undisclosed risk that the FDA would require additional information about the vendor’s facility’s manufacturing practices; (4) that, as a result of the foregoing, the regulatory approval of OLC was reasonably likely to be delayed; and (5) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Lead Plaintiff Deadline: November 2, 2026

Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310)
Or submit your information below to learn about your rights.

Join Action

Unicycive Therapeutics, Inc.

Monetary Losses ($) *

Website URL

First Name *

Last Name *

Telephone *

Email *

Street Address

City

State

Zip Code

Purchases

1	Purchases Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date
1	Purchases Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date

Add Row

Sales

1	Sales Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date
1	Sales Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date

Add Row

Upload your trades here:

Accepted file types: xls, xlsx, doc, docx, pdf, jpg, jpeg, png, Max. file size: 50 MB, Max. files: 5.
You may redact account numbers from your uploaded documents.

File name:

File size:

Select File

Does not establish an attorney-client relationship *

By clicking this box, I acknowledge that this form is not intended to and does not establish an attorney-client relationship between myself and Faruqi & Faruqi LLP, and that the submission or receipt of information via this form, e-mail or telephone does not create an attorney-client relationship.

Case

Users to notify